These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20970244)

  • 21. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
    Offersen BV; Knap MM; Horsman MR; Verheijen J; Hanemaaijer R; Overgaard J
    Acta Oncol; 2010 Nov; 49(8):1283-7. PubMed ID: 20843171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
    Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
    Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
    Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
    Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Significance of a simple assay of urine telomerase activity for the detection of bladder cancer].
    Iwabuchi I; Mori K; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Suzuki T; Ohyama C
    Hinyokika Kiyo; 2010 Oct; 56(10):551-7. PubMed ID: 21063158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of bladder cancer by analysis of urinary fibronectin.
    Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
    Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.
    Abbate I; D'Introno A; Cardo G; Marano A; Addabbo L; Musci MD; Pagliarulo A; Correale M; Quaranta M
    Anticancer Res; 1998; 18(5B):3803-5. PubMed ID: 9854500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.
    Attallah AM; Sakr HA; Ismail H; Abdel-Hady el-SK; El-Dosoky I
    BJU Int; 2005 Aug; 96(3):334-9. PubMed ID: 16042726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer.
    Szarvas T; Singer BB; Becker M; Vom Dorp F; Jäger T; Szendroi A; Riesz P; Romics I; Rübben H; Ergün S
    BJU Int; 2011 Apr; 107(7):1069-73. PubMed ID: 20825402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
    Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
    Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.
    Yamada Y; Enokida H; Kojima S; Kawakami K; Chiyomaru T; Tatarano S; Yoshino H; Kawahara K; Nishiyama K; Seki N; Nakagawa M
    Cancer Sci; 2011 Mar; 102(3):522-9. PubMed ID: 21166959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Capponi G; Canepa G; Casazza S; Bandelloni R; Tamagno S; Puntoni M
    Anticancer Res; 2010 Nov; 30(11):4761-5. PubMed ID: 21115937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of seven screening methods in the diagnosis of bladder cancer.
    Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
    Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.